复方异丙托溴铵联合布地奈德雾化吸入治疗慢性阻塞性肺疾病急性期的疗效观察

Efficacy of compound ipratropium bromide combined with budesonide inhalation in treatment of acute phase of chronic obstructive pulmonary disease

目的探讨复方异丙托溴铵与布地奈德雾化吸入疗法在慢性阻塞性肺疾病(COPD)急性期中的联合应用价值。方法选取该院收治的COPD患者78例,随机分为观察组和对照组,每组39例。两组患者采用复方异丙托溴铵的雾化吸入治疗,而观察组则在此基础上加用布地奈德雾化吸入的联合治疗,并分别对两组患者临床治疗、治疗前后肺功能变化、治疗前后血气变化以及不良反应发生进行比较分析。结果与对照组比较,观察组的临床治愈率和总有效率明显提高(P<0.05),治疗后肺功能,1秒用力呼气容积(FEV1)、FEV1占预计值、用力肺活量(FVC)以及血气分析[(血氧分压(Pa O2)及二氧化碳分压(Pa CO2))]均明显改善(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论复方异丙托溴铵联合布地奈德雾化吸入疗法能够有效改善COPD急性发作期患者临床指标,增强临床疗效。

[Objective] To study the clinical application value of compound ipratropium bromide combined with budesonide inhalation in the treatment of acute phase of chronic obstructive pulmonary disease. [Methods] Totally 78 patients with chronic obstructive pulmonary disease in acute phase in our hospital were randomly divided into observation group and control group with 39 cases in each group. The patients in the control group were treated with compound ipratropium bromide inhalation therapy, while the patients in the observation group were treated with compound ipratropium bromide combined with budesonide inhalation therapy. The clinical effect, changes in lung function and artery blood gas analysis, and the occurrence of adverse reactions of the patients in the two groups were compared and analyzed. [Results] Compared with the control group, the rates of clinical efficiency and total efficiency in the observation group were significantly increased （both P〈 0.05）. After treatment, the pulmonary function （FEV1, FEVI% predicted and FVC） and the blood gas （PaO2 and PaCO2） were significantly improved in the observation group （P 〈 0.05）. Compared with control group, there was no significant change in the occurrence of adverse reactions in the observation group （P 〉0.05）. [Conclusions] Compound ipratropium bromide combined with budesonide inhalation therapy could effectively improve clinical indicatnrs and clinical efficacy in patients with chronic obstructive pohnonary disease in acute phase.